MART-1 (26-35) (human)

Description:

MART-1 (26-35) has been shown to be better recognized by a number of polyclonal and monoclonal populations of tumor-reactive HLA-A*0201-restricted cytotoxic T lymphocytes (CTL) than MART-1 (27-35) (human).

Sequence:

EAAGIGILTV

General

References

Comments (0)

Name	MART-1 (26-35) (human)
Category	Cancer Research Peptides
One Letter Code	EAAGIGILTV
Three Letter Code	{Glu}{Ala}{Ala}{Gly}{Ile}{Gly}{Ile}{Leu}{Thr}{Val}
Molecular Weight	943.110
Application	Antigen-presenting Cells, Cancer Research

Lang, Karl Sebastian, et al. "HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1." Journal of Investigative Dermatology 116.6 (2001): 891-897.

Valmori, Danila, et al. "Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues." The Journal of Immunology 160.4 (1998): 1750-1758.

Chen, Qiyuan, et al. "Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects." Cancer Immunology, Immunotherapy 47.4 (1998): 191-197.

Romero, Pedro, et al. "Cytolytic T lymphocyte recognition of the immunodominant HLA-A* 0201-restricted Melan-A/MART-1 antigenic peptide in melanoma." The Journal of Immunology 159.5 (1997): 2366-2374.

van Elsas, Andrea, et al. "Peptide‐pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA‐A* 0201‐binding peptides from the Melan‐A/MART‐1 self antigen." European journal of immunology 26.8 (1996): 1683-1689.